Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $27.67.
KMTS has been the subject of several recent analyst reports. Bank of America began coverage on Kestra Medical Technologies in a research note on Monday. They set a "buy" rating and a $30.00 target price for the company. The Goldman Sachs Group began coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued a "neutral" rating and a $24.00 price objective for the company. Wolfe Research started coverage on shares of Kestra Medical Technologies in a research note on Monday. They set an "outperform" rating and a $29.00 target price on the stock. Stifel Nicolaus started coverage on shares of Kestra Medical Technologies in a report on Monday. They set a "buy" rating and a $28.00 price objective on the stock. Finally, Wells Fargo & Company started coverage on Kestra Medical Technologies in a research note on Monday. They issued an "overweight" rating and a $28.00 target price for the company.
Get Our Latest Stock Report on KMTS
Kestra Medical Technologies Stock Performance
Shares of NASDAQ KMTS traded down $0.96 during midday trading on Monday, reaching $23.06. The stock had a trading volume of 73,774 shares, compared to its average volume of 276,149. Kestra Medical Technologies has a twelve month low of $20.00 and a twelve month high of $26.06.
Kestra Medical Technologies Company Profile
(
Get Free ReportWe are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
